Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3210-3215

  Grayo, Solène ^a   Lott Desroches, Marie Catherine ^b   Dussurget, Olivier ^a,c,d   Respaud, Renaud ^b   Fontanet, Arnaud ^a   Join Lambert, Olivier ^c   Singlas, Eric ^b   Le Monnier, Alban ^a,e  

^a INSTITUT PASTEUR   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

^d USC 2020   (France)

^e Laboratoire des Listeria   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; MOXIFLOXACIN;

ALTERNATIVE MEDICINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BLOOD; BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG TISSUE LEVEL; ERADICATION THERAPY; FEMALE; IN VIVO STUDY; KINETICS; LISTERIA MONOCYTOGENES; LISTERIOSIS; NONHUMAN; ORGAN; PARENCHYMA; PHARMACODYNAMICS; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BRAIN; BRAIN DISEASES; CENTRAL NERVOUS SYSTEM BACTERIAL INFECTIONS; DISEASE MODELS, ANIMAL; LISTERIA INFECTIONS; LISTERIA MONOCYTOGENES; MICE; QUINOLINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 50949128547     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00177-08     Document Type: Article

References (45)

1. Anonymous. 2001. Guidance for industry bioanalytical method validation. U.S. Department of Health and Human Services, Washington, DC.
2. Benes, J., J. Viechova, M. Kabelkova, and B. Horova. 2002. Listerial endocarditis in a penicillin-allergic woman successfully treated with a combination of 4 drugs. Scand. J. Infect. Dis. 34:383-384.
3. Blanot, S., C. Boumaila, and P. Berche. 1999. Intracerebral activity of antibiotics against Listeria monocytogenes during experimental rhombencephalitis. J. Antimicrob. Chemother. 44:565-568.
4. Boswell, F. J., J. M. Andrews, R. Wise, and A. Dalhoff. 1999. Bactericidal properties of moxifloxacin and post-antibiotic effect. J. Antimicrob. Chemother. 43(Suppl. B):43-49.
5. Callapina, M., M. Kretschmar, A. Dietz, C. Mosbach, H. Hof, and T. Nichterlein. 2001. Systemic and intracerebral infections of mice with Listeria monocytogenes successfully treated with linezolid. J. Chemother. 13:265-269.
6. Carryn, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2003. Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model. J. Antimicrob. Chemother. 51:1051-1052.
7. Carryn, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2002. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob. Agents Chemother. 46:2095-2103.
8. Charpentier, E., and P. Courvalin. 1999. Antibiotic resistance in Listeria spp. Antimicrob. Agents Chemother. 43:2103-2108.
9. Dalhoff, A., and F. J. Schmitz. 2003. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 22:203-221.
10. Farber, J. M., and P. I. Peterkin. 1991. Listeria monocytogenes, a food-borne pathogen. Microbiol. Rev. 55:476-511.
11. Glaser, P., L. Frangeul, C. Buchrieser, C. Rusniok, A. Amend, F. Baquero, P. Berche, H. Bloecker, P. Brandt, T. Chakraborty, A. Charbit, F. Chetouani, E. Couve, A. de Daruvar, P. Dehoux, E. Domann, G. Dominguez-Bernal, E. Duchaud, L. Durant, O. Dussurget, K. D. Entian, H. Fsihi, F. Garcia-del Portillo, P. Garrido, L. Gautier, W. Goebel, N. Gomez-Lopez, T. Hain, J. Hauf, D. Jackson, L. M. Jones, U. Kaerst, J. Kreft, M. Kuhn, F. Kunst, G. Kurapkat, E. Madueno, A. Maitournam, J. M. Vicente, E. Ng, H. Nedjari, G. Nordsiek, S. Novella, B. de Pablos, J. C. Perez-Diaz, R. Purcell, B. Remmel, M. Rose, T. Schlueter, N. Simoes, A. Tierrez, J. A. Vazquez-Boland, H. Voss, J. Wehland, and P. Cossart. 2001. Comparative genomics of Listeria species. Science 294:849-852.
12. Godreuil, S., M. Galimand, G. Gerbaud, C. Jacquet, and P. Courvalin. 2003. Efflux pump Lde is associated with fluoroquinolone resistance in Listeria monocytogenes. Antimicrob. Agents Chemother. 47:704-708.
13. Goulet, V., and P. Marchetti. 1996. Listeriosis in 225 non-pregnant patients in 1992: clinical aspects and outcome in relation to predisposing conditions. Scand. J. Infect. Dis. 28:367-374.
14. Grayo, S., O. Join-Lambert, M. C. Desroches, and A. Le Monnier. 2008. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob. Agents Chemother. 52:1697-1702.
15. Grayo, S., R. Respaud, M. C. Desroches, S. Dubouch, A. Le Monnier, and E. Singlas. 2007. Modification of antibiotic pharmacokinetics due to Listeria monocytogenes infection, abstr. P05. Progr. Abstr. 16th Int. Symp. Problems Listeriosis, Savannah, GA.
16. Hof, H. 2004. An update on the medical management of listeriosis. Exp. Opin. Pharmacother. 5:1727-1735.
17. Hof, H., T. Nichterlein, and M. Kretschmar. 1997. Management of listeriosis. Clin. Microbiol. Rev. 10:345-357.
18. Hof, H., and G. Waldenmeier. 1988. Therapy of experimental listeriosis - an evaluation of different antibiotics. Infection 16(Suppl. 2):S171-S174.
19. Join-Lambert, O. F., S. Ezine, A. Le Monnier, F. Jaubert, M. Okabe, P. Berche, and S. Kayal. 2005. Listeria monocytogenes-infected bone marrow myeloid cells promote bacterial invasion of the central nervous system. Cell Microbiol. 7:167-180.
20. Keating, G. M., and L. J. Scott. 2004. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 64:2347-2377.
21. Krays, M. B., and G. Denys. 2001. Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana. Diagn. Microbiol. Infect. Dis. 40:193-198.
22. Leiti, O., J. W. Gross, and C. U. Tuazon. 2005. Treatment of brain abscess caused by Listeria monocytogenes in a patient with allergy to penicillin and trimethoprim-sulfamethoxazole. Clin. Infect. Dis. 40:907-908.
23. Marget, W., and H. P. Seeliger. 1988. Listeria monocytogenes infections-therapeutic possibilities and problems. Infection 16(Suppl. 2):S175-S177.
24. Michelet, C., J. L. Avril, C. Arvieux, C. Jacquelinet, N. Vu, and F. Cartier. 1997. Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sulfamethoxazole, or rifampin, against intracellular Listeria monocytogenes. Antimicrob. Agents Chemother. 41:60-65.
25. Michelet, C., J. L. Avril, F. Cartier, and P. Berche. 1994. Inhibition of intracellular growth of Listeria monocytogenes by antibiotics. Antimicrob. Agents Chemother. 38:438-446.
26. Michelet, C., S. L. Leib, D. Bentue-Ferrer, and M. G. Tauber. 1999. Comparative efficacies of antibiotics in a rat model of meningoencephalitis due to Listeria monocytogenes. Antimicrob. Agents Chemother. 43:1651-1656.
27. Michot, J. M., M. F. Heremans, N. E. Caceres, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Cellular accumulation and activity of quinolones in ciprofloxacin-resistant J774 macrophages. Antimicrob. Agents Chemother. 50:1689-1695.
28. Michot, J. M., C. Seral, F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2005. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob. Agents Chemother. 49:2429-2437.
29. Montgomery, M. J., P. M. Beringer, A. Aminimanizani, S. G. Louie, B. J. Shapiro, R. Jelliffe, and M. A. Gill. 2001. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 45:3468-3473.
30. Mouton, J. W., M. L. van Ogtrop, D. Andes, and W. A. Craig. 1999. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob. Agents Chemother. 43:2473-2478.
31. Mylonakis, E., E. L. Hohmann, and S. B. Calderwood. 1998. Central nervous system infection with Listeria monocytogenes. 33 years' experience at a general hospital and review of 776 episodes from the literature. Medicine (Baltimore) 77:313-336.
32. Nichterlein, T., M. Kretschmar, C. Budeanu, J. Bauer, W. Linss, and H. Hof. 1994. Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells. Antimicrob. Agents Chemother. 38:1501-1506.
33. Pestova, E., J. J. Millichap, G. A. Noskin, and L. R. Peterson. 2000. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother. 45:583-590.
34. Safdar, A., and D. Armstrong. 2003. Antimicrobial activities against 84 Listeria monocytogenes isolates from patients with systemic listeriosis at a comprehensive cancer center (1955-1997). J. Clin. Microbiol. 41:483-485.
35. Scortti, M., L. Lacharme-Lora, M. Wagner, I. Chico-Calero, P. Losito, and J. A. Vazquez-Boland. 2006. Coexpression of virulence and fosfomycin susceptibility in Listeria: molecular basis of an antimicrobial in vitro-in vivo paradox. Nat. Med. 12:515-517.
36. Seral, C., M. Barcia-Macay, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2005. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J. Antimicrob. Chemother. 55:511-517.
37. Siefert, H. M., A. Domdey-Bette, K. Henninger, F. Hucke, C. Kohlsdorfer, and H. H. Stass. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J. Antimicrob. Chemother. 43(Suppl. B):69-76.
38. Sipahi, O. R., T. Turhan, H. Pullukcu, S. Calik, M. Tasbakan, H. Sipahi, B. Arda, T. Yamazhan, and S. Ulusoy. 2008. Moxifloxacin versus ampicillin + gentamicin in the therapy of experimental Listeria monocytogenes meningitis. J. Antimicrob. Chemother. 61:670-673.
39. Stepanovic, S., G. Lazarevic, M. Jesic, and R. Kos. 2004. Meropenem therapy failure in Listeria monocytogenes infection. Eur. J. Clin. Microbiol. Infect. Dis. 23:484-486.
40. Temple, M. E., and M. C. Nahata. 2000. Treatment of listeriosis. Ann. Pharmacother. 34:656-661.
41. Van Bambeke, F., J. M. Michot, J. Van Eldere, and P. M. Tulkens. 2005. Quinolones in 2005: an update. Clin. Microbiol. Infect. 11:256-280.
42. Winslow, D. L., J. Damme, and E. Dieckman. 1983. Delayed bactericidal activity of beta-lactam antibiotics against Listeria monocytogenes: antagonism of chloramphenicol and rifampin. Antimicrob. Agents Chemother. 23:555-558.
43. Wise, R. 2003. Maximizing efficacy and reducing the emergence of resistance. J. Antimicrob. Chemother. 51(Suppl. 1):37-42.
44. Wise, R., J. M. Andrews, G. Marshall, and G. Hartman. 1999. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob. Agents Chemother. 43:1508-1510.
45. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94:13991-13996.